Abstract Renal cell carcinoma (RCC) is one of the most lethal cancers. It is frequently associated with the formation of tumor thrombi (TT), an intravascular extension of the tumor. Approximately 4% to 10% of patients with RCC have TT, which can reach the renal vein (10% to 18%), the inferior vena cava (4% to 23%), and, rarely, the right atrium (1%). These thrombi generally accompany advanced tumors, with distant metastases, and they reflect an aggressive biology. Treatment is challenging, especially […]